一项随机控制的试点研究评估了尼福洛克沙在性结肠炎患者的安全性和有效性
Hayam Ali AlRasheed1, Mahmoud S Abdallah2,3, Eman El-Khateeb4,5
1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
与梅萨拉相结合的nifuroxazide显著改善了性结肠炎 (UC) 结果,增加了缓解率并提高了与单独梅萨拉相比的生活质量. 这种组合疗法还减少了UC患者的关键炎症标志物.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 作为肠道消毒剂的nifuroxazide在UC的实验模型中显示出治疗潜力.
- 评估nifuroxazide在人类UC患者中的疗效对于潜在的新治疗策略至关重要.
研究的目的:
- 评估nifuroxazide在轻度至中度性结肠炎患者中作为梅沙胺的附加治疗的疗效和安全性.
- 确定nifuroxazide对临床疾病活性,炎症生物标志物和UC患者生活质量的影响.
主要方法:
- 一个随机,双盲,安慰剂对照试验,涉及50名患有轻度至中度UC的患者.
- 参与者接受了nifuroxazide (每天两次200毫克) 或安慰剂,两者与梅萨拉 (每天三次1克) 相结合,持续六个月.
- 疾病严重程度 (部分梅奥得分),血清炎症标志物 (CRP,NF-κB,IL-6,STAT3) 和生活质量 (IBDQ-32) 在治疗前和后被评估.
主要成果:
- 与安慰剂组相比,尼福洛克萨齐德组在部分梅奥得分和IBDQ-32得分上显示出显著更大的改善.
- 在nifuroxazide组中观察到IL-6,NF-κB,CRP和STAT3水平的显著降低.
- 尼福洛克萨齐德组的响应率为76%,而安慰剂组的响应率为56%,缓解率分别为56%和24%.
结论:
- 与梅沙胺联合使用尼福罗扎可为轻度至中度UC患者提供显著的临床益处.
- 这种组合疗法有效减少炎症,改善疾病活动,提高生活质量.
- 尼福洛克萨齐德是治疗性结肠炎的一个有前途的治疗选择.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
